Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0YFN1
|
|||
| Drug Name |
Tozorakimab
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Acute respiratory failure [ICD-11: CB41.0] | Phase 3 | [1] | |
| Chronic obstructive pulmonary disease [ICD-11: CA22; ICD-10: J40-J44, J47; ICD-9: 490-492, 494-496] | Phase 3 | [2] | ||
| Company |
AstraZeneca
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interleukin-33 (IL33) | Target Info | Inhibitor | [3] |
| KEGG Pathway | Cytosolic DNA-sensing pathway | |||
| Influenza A | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05624450) A Phase III, Multicentre, Randomised, Double-blind, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab (MEDI3506) in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen. U.S.National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT05742802) A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab (MEDI3506) in Participants With Chronic Obstructive Pulmonary Disease (COPD) With a History of Exacerbations. U.S.National Institutes of Health. | |||
| REF 3 | ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients: A structured summary of a study protocol for a randomised controlled trial. Trials. 2020 Jul 31;21(1):691. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.